cyp51A gene silencing using RNA interference in azole-resistant Aspergillus fumigatus

Area of Science:

• Medical Mycology
• Molecular Biology
• Antimicrobial Resistance

Background:

• Acquired resistance of Aspergillus fumigatus to azole antifungals is an increasing clinical challenge.
• Mutations in the cyp51A gene, encoding the azole drug target enzyme, are the primary mechanism of this resistance.

Purpose of the Study:

• To investigate the efficacy of silencing the cyp51A gene in azole-resistant Aspergillus fumigatus isolates.
• To evaluate the impact of cyp51A gene silencing on fungal susceptibility to azole compounds.

Main Methods:

• Design and application of a 21-nucleotide small-interfering RNA (siRNA) targeting the Aspergillus fumigatus cyp51A gene.
• Transfection of germinated conidia with siRNA and analysis of cyp51A mRNA levels via RT-PCR.
• Determination of minimum inhibitory concentrations (MICs) for itraconazole in treated and untreated fungal cultures.

Main Results:

• Successful transfection of Aspergillus fumigatus hyphae with siRNA.
• Significant reduction in cyp51A gene expression at a 50 nM siRNA concentration (P ≤ 0.05).
• A four-fold decrease in the minimum inhibitory concentration of itraconazole for siRNA-treated cells (from 16 to 4 μg/ml).

Conclusions:

• Silencing the cyp51A gene is a viable strategy to combat azole resistance in Aspergillus fumigatus.
• siRNA-mediated cyp51A gene knockdown can restore susceptibility to azole antifungals.
• This approach holds potential for developing novel therapeutic strategies against resistant fungal infections.